GeoVax Labs, Inc. (Nasdaq: GOVX) announced a strategic portfolio prioritization that will concentrate resources on its lead programs GEO-MVA and Gedeptin, while discontinuing active development of its GEO-CM04S1 COVID-19 vaccine candidate. The decision, disclosed in a press release on May 26, 2026, reflects the company's assessment of market conditions, regulatory pathways, and commercialization potential.
The discontinuation of the COVID-19 vaccine program was not based on safety concerns, according to the company, but on the continued evolution and contraction of the global COVID-19 vaccine market. GeoVax emphasized that portfolio prioritization is a standard practice in biotechnology, allowing companies to align resources with the highest-value opportunities as market conditions and scientific landscapes evolve.
GEO-MVA, GeoVax's Modified Vaccinia Ankara (MVA) vaccine candidate targeting mpox and smallpox, is advancing under an expedited regulatory pathway supported by European Medicines Agency (EMA) scientific advice. This pathway could enable approval based on a single pivotal immunobridging study demonstrating non-inferiority to an approved MVA vaccine, significantly accelerating development timelines and reducing clinical risk. The company has manufactured and released clinical-grade material for the planned Phase 3 immunobridging study. Following successful completion, GEO-MVA is expected to move toward regulatory submission and potential commercialization, including potential Emergency Use Licensing.
GeoVax has initiated outreach with global procurement and preparedness stakeholders, including government agencies, international organizations, and biodefense programs, to support potential vaccine supply agreements. These activities position GEO-MVA to serve as a critical additional supplier of MVA-vaccine, supporting supply-chain resilience and biodefense preparedness.
In the oncology space, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy (GDEPT) platform. The company's planned Phase 2 study (AdPNP-203) will evaluate Gedeptin in combination with pembrolizumab and fludarabine in a neoadjuvant setting, with the objective of enhancing tumor immune visibility and improving clinical outcomes. Gedeptin's tumor-targeting mechanism is designed to damage or destroy treated lesions through localized generation of a potent chemotherapeutic agent and may sensitize tumors to checkpoint inhibitors by exposing neoantigens from treated lesions.
The decision to prioritize Gedeptin aligns with the rapidly evolving oncology landscape, highlighted by the KEYNOTE-689 Phase 3 trial demonstrating improved event-free survival with neoadjuvant checkpoint inhibitor therapy in resectable head and neck cancers. GeoVax believes Gedeptin's mechanism may expand response rates and improve durability of outcomes in patients who derive limited benefit from checkpoint inhibition alone.
David Dodd, Chairman and Chief Executive Officer of GeoVax, stated, “GeoVax is at an important inflection point, and this decision reflects a deliberate and disciplined focus on the programs we believe can deliver the greatest near-term and long-term value. As GEO-MVA advances toward clinical validation and potential commercialization, and as Gedeptin gains relevance within emerging immuno-oncology treatment paradigms, we are aligning our resources to support focused execution against these high-potential opportunities.”
By concentrating efforts on these two programs, GeoVax aims to position itself for a more focused, execution-driven path toward late-stage development, commercialization, and long-term value creation. Further information about the company's programs can be found at GeoVax's website.
